BioSpace News Archive

Imagin Medical reported financial results for the three months ended March 31, 2020.

Oncopeptides AB announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the directed share issue which was carried out in May 2020.

IRADIMED CORPORATION, announced that its Board of Directors has appointed Roger Susi to resume his duties as the Company’s President and Chief Executive Officer after the departure of Leslie McDonnell, who separated from the Company effective May 28, 2020.

Open pivotal study inpediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval

Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response

Deal upsized to US$37 million from US$30 million, based on strong investor demand

COVID-19 tests will be distributed each week to St. Louis area Federally Qualified Health Centers

Combination therapy with pelareorep activates a profound inflammatory response

Bristol Myers Squibb announced that it will hold a virtual three part investor series during the week of June 22, 2020.

AVEO Oncology announced the presentation of results from the final analysis of overall survival in its pivotal Phase 3 TIVO-3 trial comparing tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma.